Benefit Assessment Sample Clauses
Benefit Assessment. If the IESO determines, pursuant to Section 4.4 of this Agreement, that the Supplier fails the Verification Process in respect of one or more Facilities for one or more hours, the IESO shall forthwith conduct an assessment (a “Benefit Assessment”) on a timely basis in relation to such applicable hours for the purpose of determining whether and, if so, to what extent, the Supplier and/or Atura has benefitted. The Benefit Assessment will be conducted by the IESO in accordance with Schedule 5.1 to this Agreement. The IESO shall make reasonable best efforts to complete any Benefit Assessment no later than one year from the event(s) determined by the IESO to constitute withholding in accordance with section 4.4. Notwithstanding the foregoing, where such Benefit Assessment is not completed by the IESO within four months of receipt of all representations from the Supplier in respect of the Benefit Assessment or from the date the Supplier confirms no representations will be provided, the IESO will provide Notice to the Supplier that will provide a reasonably detailed update of the status of such assessment.
Benefit Assessment. Section 2.1.
Benefit Assessment. If the IESO determines, pursuant to Schedule 4.4.1.1 or Schedule 4.4.1.2, as applicable, and including reasonably considering any representations from the Supplier, that there has been physical and/or economic withholding by one or more Facilities in one or more hours, the IESO will conduct a benefit assessment to determine the net benefit to the Supplier and Atura that resulted from such withholding. In particular, the IESO will assess by simulation what market prices/relevant uplift payments (such as, but not limited to, CMSCs, PCG and GCG) would have prevailed if available capacity had been offered (i.e., no physical withholding in accordance with Schedule 4.4.1.1) and at prices that did not exceed relevant costs (i.e., no economic withholding in accordance with Schedule 4.4.1.2). Where such an assessment indicates no simulated impact on market prices/ relevant uplift payments (such as, but not limited to, CMSCs, PCG and GCG), the IESO will not, unless there is compelling evidence otherwise, determine that the Supplier and/or Atura benefitted from the withholding. Where the IESO determines that the Supplier and/or Atura did not benefit from the withholding, the IESO will report this finding forthwith to the Supplier and Atura. Where such an assessment indicates a simulated increase in market prices/relevant uplift payments (such as, but not limited to, CMSCs, PCG and GCG), the IESO will, unless there is compelling evidence otherwise, investigate the net benefit to the Supplier and Atura. Any assessment of benefit will reasonably consider all of the Supplier’s and Atura’s relevant costs and revenues, which may include but are not limited to: cost parameters, consistent with Schedule 4.4.1.2; IESO contracts, inclusive of all elements considered in the calculation of the total payment; other contracts, if applicable; OEB rate regulation, including OEB approved variance accounts; and, any other relevant market-based revenues and costs. The benefit will be assessed on a net basis taking into account all of these costs and revenues, as well as additional costs and benefits reasonably determined by the Parties, and will be based on the cumulative result for both the Supplier and Atura.
Benefit Assessment. A Benefit Assessment applies associated with the Sanitary Subdistrict improvements in the amount of $ per equivalent living unit.
Benefit Assessment. This is a healthy participant study, and there is no direct benefit to study participants.
Benefit Assessment. Evaluation of the serum and lesional skin from patients with HS compared to healthy volunteers suggests that HS is a condition driven by neutrophils (▇▇▇▇▇▇▇▇▇▇, 2021). Reduction in migration of neutrophils to the skin of patients with HS in participants randomized to the RIST4721 treatment arm may have an improvement in their HS condition. Additionally, participation in this study may help generate future benefit for larger groups of subjects with HS if RIST4721 proves to be successful in treating this condition. Please refer to RIST4721 IB for additional details.